tbuckley/cabot-search huggingface dataset:
Medical Genetics
Authors: David Yi-Yung Hsia
Journal: New England Journal of Medicine (1960)

Indirect MeasurementsA number of hereditary conditions in which the heterozygote can only be detected by means of indirect measurements deserve consideration. In von Gierke's disease it has not been possible to demonstrate a deficiency of glucose-6-phosphatase directly, since this would involve performance of a liver biopsy on a perfectly healthy parent. However, it has been possible to identify a carrier of this abnormal gene by measuring the glucose-6-phosphate (G-6-P) and fructose-6-phosphate (F-6-P) content of the red cells after separation on a Dowex-1 column.146 It was found that the mean G-6-P was 0.18 ± 0.12 (range, 0.05–0.37) gm. per 100 . . .
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Authors: Sima Jeha, Bassem Razzouk, Michael Rytting, Susan Rheingold, Edythe Albano, Richard Kadota, Lori Luchtman-Jones, Lisa Bomgaars, Paul Gaynon, Stewart Goldman, Kim Ritchey, Robert Arceci, Arnold Altman, Kimo Stine, Laurel Steinherz, Peter Steinherz
Journal: Journal of Clinical Oncology (2009)

Purpose To determine the efficacy and safety of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia (AML). Patients and Methods A phase II, open-label, multicenter study was conducted with single-agent clofarabine in pediatric patients with refractory or relapsed AML. Clofarabine was administered intravenously over 2 hours at the pediatric maximum-tolerated dose (MTD) of 52 mg/m 2 daily for 5 consecutive days. Cycles were repeated every 2 to 6 weeks. Responses determined by an independent response review panel. Results The 42 patients treated on the study had a median age of 13 years (range, 2 to 22 years) and had received a median number of two (range, one to five) prior regimens. The response rate was 26% and included one complete response without platelet recovery and 10 partial responses. The median duration of response was 20 weeks (range, 2 to ≥ 156 weeks). Six of 28 patients who were refractory to the immediately preceding therapy achieved response. Thirteen patients (31%), including seven responders, proceeded to hematopoietic stem-cell transplantation (HSCT) after treatment with clofarabine and survived between 24 to ≥ 160 weeks. Five patients (12%) remain alive post-transplantation at ≥ 63, ≥ 71, ≥ 86, ≥ 114, and ≥ 130 weeks. The most common grade 3 or greater adverse events without regard to causality were febrile neutropenia, catheter-related infection, epistaxis, hypotension, nausea, and fever. Transient elevation of liver enzymes and hypokalemia occurred frequently. Five patients died within 30 days of clofarabine administration secondary to progressive disease, and another five died as a result of an adverse event. Conclusion Clofarabine is active in pediatric patients with multiply relapsed or refractory AML. Responses allowed several refractory patients to proceed to HSCT. The toxicity profile was expected in this patient population.
“Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.” Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. <i>Eur Respir J</i> 2016; 47: 1776–1784.
Authors: Marjolaine Georges, Elise Morawiec, Mathieu Raux, Jésus Gonzalez-Bermejo, Pierre-François Pradat, Thomas Similowski, Capucine Morélot-Panzini
Journal: European Respiratory Journal (2016)
Immunofluorescence studies in a case of Goodpasture's syndrome
Authors: B. C. Sturgill
Journal: JAMA (1965)

THE ASSOCIATION of glomerulonephritis and hemorrhagic pneumonitis was first described by Goodpasture<sup>1</sup>in 1919, but only in the past ten years has serious consideration been given to the idea that this represents a distinct clinical and pathologic entity. During this time, nearly 100 cases have been reported and recently reviewed.<sup>2</sup>Although the etiology is not known, the recent demonstration of γ-globulin localization in glomeruli has suggested that, as in glomerulonephritis, an immunologic mechanism is responsible for the renal lesion.<sup>3</sup> The present report confirms the finding of γ-globulin localization in the glomerular basement membrane and shows for the first time localization of γ-globulin in the alveolar septa. This suggests that the renal and pulmonary lesions are caused by the same mechanism. <h3>Report of a Case</h3> A 17-year-old white boy had scarlet fever at the age of 13, but the disease apparently was not complicated and recovery was uneventful.
Different types of chronic hepatitis in alcoholic patients: Does chronic hepatitis induced by alcohol exist?
Authors: S Takase
Journal: Hepatology (1991)

To verify the existence of chronic hepatitis induced by alcohol, the clinicopathological features of chronic hepatitis in heavy drinkers were studied using various viral markers. Histological features of chronic active hepatitis were seen in 27 heavy drinkers. These patients were divided into four groups. The AL group (seven cases) consisted of alcoholics who were negative for both hepatitis C antibody and HBsAg; the HB group (four cases) was positive for HBsAg; the HC1 group (seven cases) was positive for hepatitis C antibody but negative for hepatitis C virus–RNA genome; and the HC2 group (nine cases) was positive both for hepatitis C antibody and hepatitis C virus–RNA genome. Serum AST and ALT activity declined during 4 wk of abstinence in most patients in the AL group and in the HC1 group. The response of serum AST and ALT to abstinence was poor in most patients in the HB group and the HC2 group. Serum desialo-transferrin and alcohol liver membrane antibodies were detected more frequently in the sera of patients in the AL group and HC1 group. A trend toward increased frequency of centrilobular ballooning existed in the AL group, but this did not reach statistical significance. These results suggest that chronic active hepatitis in patients in the AL group, in whom markers of HBV and hepatitis C virus were absent, may be caused by alcohol. Patients in the HC1 group who had hepatitis C antibody but not hepatitis C virus–RNA may represent cases where both alcohol and hepatitis C virus are involved. (HEPATOLOGY 1991;13:876–881.)
BOOK REVIEWS
Authors: F. C. SZOKA
Journal: JNCI Journal of the National Cancer Institute (1989)

BOOK REVIEWS Get access Liposomes in the Therapy of Infectious Diseases and Cancer, UCLA Symposia on Molecular and Cellular Biology New Series, Volume 89. G. Lopez-Berestein, I. J. Fidler, eds. New York: Alan R. Liss, Inc., 1989, 500 pp. $96. FRANCIS C. SZOKA FRANCIS C. SZOKA Department of Pharmacy and Pharmaceutical Chemistry University of California San FranciscoCA 94143–0446 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 14, 19 July 1989, Pages 1102–1103, https://doi.org/10.1093/jnci/81.14.1102-a Published: 19 July 1989
Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042
Authors: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim
Journal: European Urology (2017)
Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
Authors: Insa Geffers, Katrin Serth, Gavin Chapman, Robert Jaekel, Karin Schuster-Gossler, Ralf Cordes, Duncan B. Sparrow, Elisabeth Kremmer, Sally L. Dunwoodie, Thomas Klein, Achim Gossler
Journal: The Journal of Experimental Medicine (2007)
Caffeine and ventricular arrhythmias. An electrophysiological approach
Authors: L. B. Chelsky
Journal: JAMA (1990)

Little information is known regarding caffeine's effect on the substrate supporting sustained ventricular arrhythmias. This prospective study evaluated the effect of coffee (275 mg of caffeine) on this substrate with programmed ventricular stimulation in 22 patients with a history of symptomatic nonsustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation. Patients under-went electrophysiological testing before and 1 hour after coffee ingestion. Mean ( ± SEM) plasma caffeine level achieved after coffee consumption was 6.2 ± 0.5 mg/L. Mean plasma catecholamine and potassium values were not altered significantly 1 hour following caffeine ingestion. The number of extrastimuli required to induce an arrhythmia was unchanged in 10 patients (46%), increased in six (27%), and decreased in six (27%). Rhythm severity was unchanged in 17 patients (77%), more severe in two (9%), and less severe in three (14%). In those patients with clinical ventricular arrhythmias, caffeine did not significantly alter inducibility or severity of arrhythmias, suggesting little effect on the substrate supporting ventricular arrhythmias. (<i>JAMA</i>. 1990;264:2236-2240)
DEEPER BRAIN SURGERY
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson precision medicine study.
Authors: Apostolia Maria Tsimberidou, David S. Hong, Carrie Cartwright, Jennifer J. Wheler, Gerald Falchook, Aung Naing, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, Patrick Hwu, Bryan K. Kee, Merrill S. Kies, Russell Broaddus, John Mendelsohn, Kenneth R. Hess, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2017)

2513 Background: We present outcomes for 637 patients who were referred for phase I trials and were treated under IMPACT. Methods: Patients with advanced, refractory cancer who had tumor genomic analyses were treated with matched targeted therapy (MTT) when available. Results: Overall, 1,179 (82.1%) of 1,436 patients had ≥1 alteration (median age, 59.7 yrs; men, 41.2%); 637 had ≥1 actionable aberration and were treated with MTT (n=390) or non-MTT (n=247). Patients treated with MTT had higher rates of CR and PR (11% vs. 5%; p=.0099) (Table), longer failure-free survival (FFS) (3.4 vs. 2.9 months; p=.0015), and longer overall survival (OS) (8.4 vs. 7.3 months; p = .041) than unmatched patients. Two-month landmark analyses showed that, for MTT patients, FFS for responders vs. non-responders was 7.6 vs. 4.3 months (p&lt;.0001) and OS was 23.4 vs. 8.5 months (p&lt;.0001); for non-MTT patients (responders vs. non-responders), FFS was 6.6 vs. 4.1 months (p=.0005) and OS was 15.2 vs. 7.5 months (p = .43). Patients with both PI3K and MAPK pathway alterations matched to PI3K/Akt/mTor axis inhibitors alone showed outcomes comparable to unmatched patients. Conclusions: Matched versus unmatched patients had significantly better outcomes. For matched responders, median survival reached almost two years. However, matching patients who harbor both a PI3K and a MAPK pathway alteration to only a PI3K pathway inhibitor did not improve outcome. Clinical trial information: NCT00851032. [Table: see text]
Charity care takes many forms
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Young bones
Authors: C Douglas
Journal: BMJ (1994)

The ability of Ag-primed B cells to recruit distinct Th subsets was examined using two analogous synthetic peptides, G41CT3 and G28CT3, as model Ags. With sequence differences at only two positions, these peptides were identical both with respect to fine specificity of Abs induced and ability to prime T cells. Lymph node cell populations primed with peptide G41CT3, when challenged with the homologous Ag, yielded predominantly Th2 cytokines. In contrast, a challenge with the heterologous Ag, G28CT3, resulted in a markedly increased production of Th1 cytokines. These distinctions derived from altered APC function of Ag-primed B cells due to differential kinetics of recognition of the two Ags by surface Ig receptors, as confirmed by binding studies with a panel of anti-G41CT3 mAbs. A concentration-dependent circular dichroism study revealed differences in the nature of intermolecular associations for these two peptides. Furthermore, the on-rate of peptide G28CT3 binding to Ab also increased with increasing peptide concentration, implying a dependence on intermolecular interactions. This, in turn, correlated well with the ability of peptide G28CT3 to preferentially activate either Th1 or Th2 cells. Thus, the relative proportion of Th1 vs Th2 cells recruited by Ag-primed B cells is governed by the on-rate of Ag binding to surface Ig receptors, with higher on-rates promoting Th1 recruitment. Further, even subtle changes in solution behavior of an Ag can markedly influence the kinetics of recognition by B cells.
吸烟和社会经济地位与黑色素瘤皮肤癌的关联
Authors: J.A.G. Gibson, T.D. Dobbs, R. Griffiths, J. Song, A. Akbari, S. Whitaker, A. Watkins, S.M. Langan, H.A. Hutchings, R.A. Lyons, I.S. Whitaker
Journal: British Journal of Dermatology (2020)

皮肤癌是西方人群最常见的癌症类型,而黑色素瘤是最危险的疾病形式。近年来,出现了“社会决定因素”和黑色素瘤之间的联系。社会决定因素包括社会经济因素(包括收入、教育、贫困水平、居住地区、职业和社会状况)和生活方式因素(包括紫外线暴露情况、婚姻状况、业余爱好、吸烟、肥胖)。 本研究由位于英国斯旺西和伦敦的一组研究人员进行,旨在重新分析人们的吸烟习惯及社会经济地位与黑色素瘤发生和进展之间的关系。 为了实现这一目标,团队使用了一个群体数据库,该数据库提供了在威尔士诊断和治疗的患者的详细信息。研究者们能够分析在本研究中包括的过去 5 年里超过 9000 名诊断患有黑色素瘤的患者中的数据,此外,他们还审查了 26000 名无黑色素瘤患者的信息。 他们发现,吸烟与黑色素瘤的发生率下降相关,并且它对黑色素瘤本身造成的死亡率没有影响,尽管吸烟者中其他原因导致的死亡率高于非吸烟者。 在社会经济地位较高的人群中,黑色素瘤发生率也更高,但是这些个体与社会经济地位较低的人相比,黑色素瘤生存率也更高。 这些发现的解释需要澄清,因为差异可能是由于吸烟对黑色素瘤发生和进展的直接影响,或者可能与其他因素(例如吸烟者和非吸烟者之间的日晒率)有关。 本摘要涉及研究:吸烟和社会经济地位与皮肤黑色素瘤的关联:基于人群、数据联系、病例对照研究。
Vaccinial Keratitis Treated with IDU
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL NEWS
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors
Authors: M Tacke
Journal: Hepatology (1997)

The second envelope protein (E2) of the hepatitis G virus (HGV) was expressed in Chinese hamster ovary (CHO) cells and showed a molecular weight of approximately 60 to 70 kd, with 15 to 25 kd of the size contributed by N-linked glycosylation. An enzyme-linked immunosorbent assay (ELISA) using HGV-E2 was developed to test for antibodies to this protein (anti-E2) in human sera. High sensitivity was achieved by developing monoclonal antibodies (mAbs) to HGV-E2, which were used as capture antibodies in the ELISA. Our studies revealed that 16% of healthy Spanish blood donors were exposed to HGV, indicating that additional routes of viral transmission besides parenteral exposure might exist. An even higher prevalence of exposure to HGV (52%-73%) was found in several groups at risk of parenteral exposure to infectious agents, i.e., intravenous drug users, transfusion history, hemophiliacs, and hepatitis C virus (HCV)-positive patients. Most anti-E2-positive patients were HGV-RNA-negative and vice versa, indicating an inverse correlation of these two viral markers. A panel of 16 posttransfusion patients followed for up to 16 years revealed that patients who develop an anti-E2 response become HGV-RNA-negative, while patients who do not develop anti-E2 are persistently infected. Immunity to HGV seems to be long-lasting, because circulating antibody to E2 could still be detected 14 years after seroconversion. Sequence comparisons showed that E2 is highly conserved among isolates collected worldwide, indicating that immune escape variants are not common in HGV infections. This reflects on a molecular level why HGV infections usually are cleared spontaneously by the host. However, possible mechanisms of HGV persistence, as found in some patients, remain to be elucidated.
An analysis of ambulance accidents in Tennessee
Authors: P. S. Auerbach
Journal: JAMA (1987)

In an effort to improve our program for ambulance crash and related injury prevention, we analyzed 102 consecutive ambulance accidents. Incidents reported included those that resulted in human injury or in which property damage exceeded $200. Multiple logistic regression was used to determine the association between circumstances reported at the time of the accidents and the risk of injury. Twenty-nine accidents contributed to a total of 65 injured victims, with one death. The variable most strongly associated with the probability of an injury-accident was use of a passenger restraint device. Darkness and occurrence at an intersection were variables showing increased risk, but were not statistically significant. The interaction of variables did not have a combined influence on the incidence of injury. The mean delay to hospital care after an accident was 9.4 minutes. Based on our data, we conclude that passenger restraints for both ambulance attendants and passengers should be mandatory, and we suggest that traffic signals be strictly heeded at intersections and speed limits in urban settings be obeyed. (<i>JAMA</i>1987;258:1487-1490)
THE CHICAGO SESSION
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal